Aurobindo Pharma Launches Generic Advair Diskus in US Inhalation Market
Aurobindo Pharma, through its subsidiary Lannett Company LLC, has launched a generic version of GSK's Advair Diskus in the US market, available in 100/50 mcg and 250/50 mcg strengths. This marks the company's entry into the US inhalation market and the first product from its inhalation pipeline to reach the US. The drug treats asthma and chronic obstructive pulmonary disease, representing a strategic expansion into complex respiratory generics beyond conventional oral formulations.
First-hand measurement across 3 sources
We measured how 3 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (60/100). Lens Score 38/100.
Outlets measured: economictimes, news18, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (50–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 31 Aug, 08:26 am. Other outlets followed.